Promis Diagnostics, Inc
1 known investors
Find your way into Promis Diagnostics, Inc
Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.
Investors · 1
Competitors · 5
by search overlapCareDx7 shared keywordsCareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
MDxHealth6 shared keywordsMDxHealth is a commercial-stage precision diagnostics company offering molecular diagnostic tests to guide the diagnosis and treatment of prostate cancer and other urologic diseases. Its tests use proprietary genetic, epigenetic, and molecular technologies and serve physicians, patients, payers, and providers.
Foresight Diagnostics6 shared keywordsForesight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types. Its offerings support oncology drug development, clinical trials, and patient care for academic and biopharma partners.
Pinkdx5 shared keywordsPinkDx is a diagnostics company developing tests, led by a leadership team spanning scientific, medical, and business functions.
Earlydx5 shared keywordsEarlyDx develops non-invasive liquid biopsy tests aimed at early cancer detection and precision medicine. The company positions its tests as accurate and affordable diagnostics.
Companies competing with Promis Diagnostics, Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Promis Diagnostics, Inc do?
- Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.
- Who are Promis Diagnostics, Inc's investors?
- Promis Diagnostics, Inc's investors include Solidus Investment.